A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.

by Tjeerd-Pieter van Staa, Hubert G Leufkens, Bill Zhang, Liam Smeeth
Published 2009-12-01

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars

by Ali M. Alsamil, Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens, Helga Gardarsdottir
Published 2021-02-01

Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction

by Charlotte Rietbergen, Gudrun Stefansdottir, Hubert G. Leufkens, Mirjam J. Knol, Marie L. De Bruin, Marie L. De Bruin, Irene Klugkist, Irene Klugkist
Published 2018-02-01

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia

by Denis Kibira, Denis Kibira, Cornelia Asiimwe, Moses Muwonge, Hendrika A. van den Ham, Tim Reed, Hubert G. Leufkens, Aukje K. Mantel-Teeuwisse
Published 2021-04-01

Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics bet...

by Denis Kibira, Anthony Ssebagereka, Hendrika A. van den Ham, Jimmy Opigo, Henry Katamba, Morries Seru, Tim Reed, Hubert G. Leufkens, Aukje K. Mantel-Teeuwisse
Published 2021-03-01

Intensive Monitoring Studies for Assessing Medicines: A Systematic Review

by Carla Torre, Carla Torre, Maria Cary, Fábio Cardoso Borges, Paula S. Ferreira, Paula S. Ferreira, Joana Alarcão, Hubert G. Leufkens, João Costa, João Costa, Ana Paula Martins
Published 2019-07-01

Regulatory scientific advice on non-inferiority drug trials.

by Grace Wangge, Michelle Putzeist, Mirjam J Knol, Olaf H Klungel, Christine C Gispen-De Wied, Antonius de Boer, Arno W Hoes, Hubert G Leufkens, Aukje K Mantel-Teeuwisse
Published 2013-01-01